Table 1.
Patient characteristics.
| Primary tumor | Age in yrs | Mean baseline VAS pain score | Mean VAS pain score at day 5–7 |
|---|---|---|---|
| Breast | 78 | 7 | 4 |
| Breast | 52 | 6 | 2 |
| Breast | 72 | 7 | 4 |
| Breast | 51 | 6 | 2 |
| Breast | 71 | 7 | 2 |
| Breast | 34 | 6 | 3 |
| Breast | 71 | 7 | 4 |
| Breast | 42 | 9 | 3 |
| Breast | 47 | 7 | 3 |
| Breast | 71 | 6 | 4 |
| Breast | 69 | 5 | 3 |
| Breast | 75 | 8 | 4 |
| Breast | 44 | 6 | 3 |
| Breast | 57 | 7 | 4 |
| Breast | 68 | 6 | 3 |
| Breast | 76 | 8 | 5 |
| Breast | 50 | 8 | 3 |
| Breast | 61 | 6 | 2 |
| Breast | 42 | 8 | 3 |
| Breast | 66 | 7 | 4 |
| Renal Cell Carcinoma | 69 | 7 | 5 |
| Renal Cell Carcinoma | 61 | 6 | 4 |
| Renal Cell Carcinoma | 51 | 7 | 3 |
| Renal Cell Carcinoma | 56 | 7 | 3 |
| Renal Cell Carcinoma | 62 | 8 | 5 |
| Urothelium Carcinoma | 74 | 7 | 7 |
| Urothelium Carcinoma | 69 | 7 | 3 |
| Urothelium Carcinoma | 64 | 8 | 5 |
| Bronchial Carcinoma | 63 | 8 | 7 |
| Bronchial Carcinoma | 52 | 8 | 2 |
| Malignant Melanoma | 57 | 7 | 3 |
| Malignant Melanoma | 67 | 6 | 3 |
| Neuroendocrine tumor | 33 | 7 | 3 |